An observational study in Dry Eye Symptoms, sponsored by Yifeng Yu. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Yifeng Yu · Observational
To compare the prevalence of dry eye symptoms and to investigate the association of the risk factors with the dry eye symptomatology among university students in the epidemic and non-epidemic areas of China under the COVID-zero strategy.
As the COVID-19 outbreak at the end of 2019 spread around the world, the World Health Organization declared it a public health emergency of international concern on 30th January, and a global pandemic on 1st March. In addition to the threat of coronavirus itself, anti-epidemic measures such as wearing masks, maintaining social distance, prohibiting group gathering, blockade, isolation, curfew, closure, working at home, online learning, etc., have also greatly changed people's daily life dynamics. Unlike the previous regional blockade (city-wide) suspension of school and work, China has shifted to dynamic prevention and control in April 2020, and the basic life and activities in the epidemic area are not restricted. This study aims to compare the prevalence of dry eye symptoms and to investigate the association of the risk factors with dry eye symptoms among college students in the epidemic and non-epidemic areas of China under the dynamic COVID-zero strategy.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 1,807 is above the median of 90 across 171 observational studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Yifeng Yu is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The subjects of the study are students from Nanchang University and Henan University.
Exclusion criteria:
A score of ocular surface disease index (OSDI)questionnaire
Ocular surface disease index (OSDI)questionnaire : (1) OSDI: ≤12 (no DED symptoms), 13 ≤ d ≤ 22 (mild DED symptoms), 23 ≤ d ≤ 32 (moderate DED symptoms), and ≥33 (severe DED symptoms).
Time frame: DAY 0
A score of GAD-7 questionnaire
GAD-7 questionnaire: (1) 0 \< GAD-7 ≤ 4 (normal), 5 ≤ GAD-7 ≤ 9 (mild anxiety), 10 ≤ GAD-7 ≤ 13 (moderate anxiety), 14 ≤ GAD-7 ≤ 18 (moderate and severe anxiety), and 19 ≤ GAD-7 ≤ 21 (severe anxiety).
Time frame: DAY 0
A score of PHQ-9 questionnaire
PHQ-9 questionnaire: (1) 0 \< PHQ-9 ≤ 4 (normal), 5 ≤ GAD-7 ≤ 9 (mild depression), 10 ≤ GAD-7 ≤ 14 (moderate depression), 15 ≤ GAD-7 ≤ 19 (moderate and severe depression), and 20 ≤ GAD-7 ≤ 27 (severe depression).
Time frame: DAY 0
A score of UCLA Loneliness Scale questionnaire
UCLA Loneliness Scale Questionnaire: (1) UCLA \< 28 (low loneliness), 28 ≤ UCLA ≤ 33 (generally lower), 33 \< UCLA ≤ 39 (intermediate level), 39 \< UCLA ≤ 44 (generally higher), and GAD-7 \> 44 (highly lonely).
Time frame: DAY 0
Students' increased use of mobile phones
Students choose to increase the time of using mobile phones according to options: 0 hours, less than 1 hour, 1-3 hours, 3-5 hours, 5-7 hours, and more than 7 hours
Time frame: DAY 0
Frequency of student sports
Students choose the frequency of sports according to the options, which are: less than once a month, 2-3 times a month, 1-2 times a week, 3-5 times a week, and once a day.
Time frame: DAY 0
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.